Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

Andrew Blauvelt; Craig L. Leonardi; Melinda Gooderham; Kim A. Papp; Sandra Philipp; Jashin J. Wu; Atsuyuki Igarashi; Mary Flack; Ziqian Geng; Tianshuang Wu; Anne Camez; David Williams; Richard G. Langley

doi:10.1001/jamadermatol.2020.0723

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

Andrew Blauvelt, Craig L. Leonardi, Melinda Gooderham, Kim A. Papp, Sandra Philipp, Jashin J. Wu, Atsuyuki Igarashi, Mary Flack, Ziqian Geng, Tianshuang Wu, Anne Camez, David Williams, Richard G. Langley

科研成果: 期刊稿件 › 文章 › 同行评审

149 引用（Scopus）

源语言	英语
页（从-至）	649-658
页数	10
期刊	JAMA Dermatology
卷	156
期	6
DOI	https://doi.org/10.1001/jamadermatol.2020.0723
出版状态	已出版 - 6月 2020
已对外发布	是

!!!ASJC Scopus Subject Areas

皮肤医学

访问文件

10.1001/jamadermatol.2020.0723

其它文件与链接

引用此

Blauvelt, A., Leonardi, C. L., Gooderham, M., Papp, K. A., Philipp, S., Wu, J. J., Igarashi, A., Flack, M., Geng, Z., Wu, T., Camez, A., Williams, D., & Langley, R. G. (2020). Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial. JAMA Dermatology, 156(6), 649-658. https://doi.org/10.1001/jamadermatol.2020.0723

Blauvelt, A, Leonardi, CL, Gooderham, M, Papp, KA, Philipp, S, Wu, JJ, Igarashi, A, Flack, M, Geng, Z, Wu, T, Camez, A, Williams, D & Langley, RG 2020, 'Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial', JAMA Dermatology, 卷 156, 号码 6, 页码 649-658. https://doi.org/10.1001/jamadermatol.2020.0723

@article{a4f9ab74e22641e0a00f83a330d67bfd,

title = "Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial",

author = "Andrew Blauvelt and Leonardi, {Craig L.} and Melinda Gooderham and Papp, {Kim A.} and Sandra Philipp and Wu, {Jashin J.} and Atsuyuki Igarashi and Mary Flack and Ziqian Geng and Tianshuang Wu and Anne Camez and David Williams and Langley, {Richard G.}",

year = "2020",

month = jun,

doi = "10.1001/jamadermatol.2020.0723",

language = "English",

volume = "156",

pages = "649--658",

journal = "JAMA Dermatology",

issn = "2168-6068",

publisher = "American Medical Association",

number = "6",

}

TY - JOUR

T1 - Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis

T2 - A Phase 3 Randomized Clinical Trial

AU - Blauvelt, Andrew

AU - Leonardi, Craig L.

AU - Gooderham, Melinda

AU - Papp, Kim A.

AU - Philipp, Sandra

AU - Wu, Jashin J.

AU - Igarashi, Atsuyuki

AU - Flack, Mary

AU - Geng, Ziqian

AU - Wu, Tianshuang

AU - Camez, Anne

AU - Williams, David

AU - Langley, Richard G.

PY - 2020/6

Y1 - 2020/6

UR - http://www.scopus.com/inward/record.url?scp=85083506413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083506413&partnerID=8YFLogxK

U2 - 10.1001/jamadermatol.2020.0723

DO - 10.1001/jamadermatol.2020.0723

M3 - Article

C2 - 32267471

AN - SCOPUS:85083506413

SN - 2168-6068

VL - 156

SP - 649

EP - 658

JO - JAMA Dermatology

JF - JAMA Dermatology

IS - 6

ER -

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial

!!!ASJC Scopus Subject Areas

访问文件

其它文件与链接

指纹

引用此